InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2023-07-12 | Daniel Goldman(D-NY10) | house | Sale | $15,001 - $50,000 |
| 2023-03-06 | Daniel Goldman(D-NY10) | house | Purchase | $15,001 - $50,000 |
| 2023-01-31 | Daniel Goldman(D-NY10) | house | Sale | $1,001 - $15,000 |
| 2021-10-19 | Thomas Suozzi(D-NY03) | house | Purchase | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenues | $245.7M-0.8% | $247.8M+154.8% | $97.3M+442.0% | $17.9M+17.8% | $15.2M |
| Cost of product sales (excluding amortization of acquired developed technologies) | $503.3M+12.9% | $445.7M+2.3% | $435.6M-19.4% | $540.5M+22.6% | $440.8M |
| Selling, general and administrative | $1.81B+30.6% | $1.39B+3.1% | $1.34B-5.2% | $1.42B-2.4% | $1.45B |
| Research and development | $782.7M-11.5% | $884.0M+4.0% | $849.7M+43.9% | $590.5M+16.7% | $505.7M |
| Intangible asset amortization | $654.7M+4.4% | $627.3M+3.1% | $608.3M+1.5% | $599.2M+14.0% | $525.8M |
| Acquired in-process research and development | $947.9M+9378.6% | $10.0M-47.4% | $19.0M-95.7% | $444.1M | $0 |
| Total operating expenses | $4.70B+40.1% | $3.35B+3.0% | $3.26B-12.6% | $3.72B+27.4% | $2.92B |
| Income (loss) from operations | -$430.2M-160.0% | $716.6M+23.9% | $578.6M+983.0% | -$65.5M-138.5% | $170.3M |
| Interest expense, net | -$195.1M+18.1% | -$238.1M+17.7% | -$289.4M-0.4% | -$288.2M-3.4% | -$278.8M |
| Foreign exchange gain (loss) | -$2.6M+68.6% | -$8.2M-193.1% | $8.8M+146.2% | -$19.0M-337.1% | -$4.3M |
| Income (loss) before income tax benefit and equity in loss of investees | -$627.9M-233.5% | $470.4M+57.9% | $297.9M+179.9% | -$372.8M | — |
| Income tax benefit | -$272.4M-198.0% | -$91.4M+23.8% | -$119.9M+24.4% | -$158.6M | — |
| Equity in loss of investees | $732K-55.9% | $1.7M-44.8% | $3.0M-69.7% | $9.9M+1289.5% | $714K |
| Net income (loss) | -$356.1M-163.6% | $560.1M+35.0% | $414.8M+285.1% | -$224.1M+32.0% | -$329.7M |
| Basic (in dollars per share) | -$6K-164.5% | $9K+38.3% | $7K+283.0% | -$4K+35.1% | -$6K |
| Diluted (in dollars per share) | -$6K-167.5% | $9K+41.8% | $6K+270.4% | -$4K+35.1% | -$6K |
| Weighted-average ordinary shares used in per share calculations - basic (in shares) | $61.0M-1.4% | $61.8M-2.3% | $63.3M+1.2% | $62.5M+4.8% | $59.7M |
| Weighted-average ordinary shares used in per share calculations - diluted (in shares) | $61.0M-7.6% | $66.0M-8.4% | $72.1M+15.2% | $62.5M+4.8% | $59.7M |
| Product sales, net | |||||
| Total revenues | $245.7M-0.8% | $247.8M+154.8% | $97.3M+442.0% | $17.9M+17.8% | $15.2M |
| Royalties and contract revenues | |||||
| Total revenues | $245.7M-0.8% | $247.8M+154.8% | $97.3M+442.0% | $17.9M+17.8% | $15.2M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
How ASCO Phase 3 Oncology Data May Reshape Jazz Pharmaceuticals' (JAZZ) Investment Narrative
Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA